A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread

Summary

This is an open-label, single-arm, prospective, multicenter clinical study designed to evaluate the efficacy and safety of envafolimab in combination with lenvatinib for the treatment of patients with clear cell renal cell carcinoma (ccRCC) accompanied by liver metastases. The Department of Urology at Fudan University Shanghai Cancer Center serves as the primary research center.

Timeline

Start

2025-12-01

Primary completion

2027-11-01

Completion

2028-05-30

Drugs

Indications